These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29396780)

  • 1. Structural identifiability for mathematical pharmacology: models of myelosuppression.
    Evans ND; Cheung SYA; Yates JWT
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):79-90. PubMed ID: 29396780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transit and lifespan in neutrophil production: implications for drug intervention.
    Câmara De Souza D; Craig M; Cassidy T; Li J; Nekka F; Bélair J; Humphries AR
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):59-77. PubMed ID: 29236223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.
    Eisenberg MC; Jain HV
    J Theor Biol; 2017 Oct; 431():63-78. PubMed ID: 28733187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: To be or not to be an identifiable model. Is this a relevant question in animal science modelling?
    Muñoz-Tamayo R; Puillet L; Daniel JB; Sauvant D; Martin O; Taghipoor M; Blavy P
    Animal; 2018 Apr; 12(4):701-712. PubMed ID: 29096725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting myelosuppression of drugs from in silico models.
    Crivori P; Pennella G; Magistrelli M; Grossi P; Giusti AM
    J Chem Inf Model; 2011 Feb; 51(2):434-45. PubMed ID: 21275392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Identifiability of Dynamic Systems Biology Models.
    Villaverde AF; Barreiro A; Papachristodoulou A
    PLoS Comput Biol; 2016 Oct; 12(10):e1005153. PubMed ID: 27792726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structure of binding curves and practical identifiability of equilibrium ligand-binding parameters.
    Middendorf TR; Aldrich RW
    J Gen Physiol; 2017 Jan; 149(1):121-147. PubMed ID: 27993951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Hematological Toxicities Using Mathematical Modeling.
    Fornari C; O'Connor LO; Yates JWT; Cheung SYA; Jodrell DI; Mettetal JT; Collins TA
    Clin Pharmacol Ther; 2018 Oct; 104(4):644-654. PubMed ID: 29604045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifiability Analysis of Three Control-Oriented Models for Use in Artificial Pancreas Systems.
    Garcia-Tirado J; Zuluaga-Bedoya C; Breton MD
    J Diabetes Sci Technol; 2018 Sep; 12(5):937-952. PubMed ID: 30095007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameter estimation for multistage clonal expansion models from cancer incidence data: A practical identifiability analysis.
    Brouwer AF; Meza R; Eisenberg MC
    PLoS Comput Biol; 2017 Mar; 13(3):e1005431. PubMed ID: 28288156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.
    Galvanin F; Ballan CC; Barolo M; Bezzo F
    J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):451-67. PubMed ID: 23733369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAISY: a new software tool to test global identifiability of biological and physiological systems.
    Bellu G; Saccomani MP; Audoly S; D'Angiò L
    Comput Methods Programs Biomed; 2007 Oct; 88(1):52-61. PubMed ID: 17707944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability.
    Sher A; Niederer SA; Mirams GR; Kirpichnikova A; Allen R; Pathmanathan P; Gavaghan DJ; van der Graaf PH; Noble D
    Bull Math Biol; 2022 Feb; 84(3):39. PubMed ID: 35132487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three novel approaches to structural identifiability analysis in mixed-effects models.
    Janzén DLI; Jirstrand M; Chappell MJ; Evans ND
    Comput Methods Programs Biomed; 2019 Apr; 171():141-152. PubMed ID: 27181677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
    Eudy RJ; Riggs MM; Gastonguay MR
    AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What do we mean by identifiability in mixed effects models?
    Lavielle M; Aarons L
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):111-22. PubMed ID: 26660913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global identifiability of linear compartmental models--a computer algebra algorithm.
    Audoly S; D'Angiò L; Saccomani MP; Cobelli C
    IEEE Trans Biomed Eng; 1998 Jan; 45(1):36-47. PubMed ID: 9444838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.
    Siripuram VK; Wright DFB; Barclay ML; Duffull SB
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):415-423. PubMed ID: 28612141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parameter Identifiability of Fundamental Pharmacodynamic Models.
    Janzén DL; Bergenholm L; Jirstrand M; Parkinson J; Yates J; Evans ND; Chappell MJ
    Front Physiol; 2016; 7():590. PubMed ID: 27994553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.